<DOC>
	<DOCNO>NCT00223977</DOCNO>
	<brief_summary>This phase 3 clinical investigation . Patients meet eligibility criterion provide sign informed consent randomize receive one two level Ferrlecit oral iron 1:1:1 ratio .</brief_summary>
	<brief_title>2 Doses Ferrlecit Versus Oral Iron Treat Iron-deficiency Anemia Peritoneal Dialysis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male female , least 18 year age . Received maintenance peritoneal dialysis therapy least 4 week . Was expect remain peritoneal dialysis therapy duration study . Had predetermine low hemoglobin transferrin saturation ( TSAT ) level . Signed patient inform consent . Had predetermine serum level Ferritin TSAT Pregnant lactating . Had serious concomitant medical disorder incompatible participation study . Had know hypersensitivity Ferrlecit component . Unable cooperate comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Anemia .</keyword>
</DOC>